Amedisys (AMED) Tops Q3 EPS by $0.16
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Amedisys Reports Third Quarter 2021 Financial Results Updates 2021 Guidance
November 2, 2021 4:05 PM EDTBATON ROUGE, La., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month periods ended September 30, 2021.
Three-Month Periods Ended September 30, 2021 and 2020
Net service revenue increased $9.4Â million to $553.5Â million compared to $544.1Â million in 2020.Net income attributable to Amedisys, Inc. of $45.0Â million compared to $72.0Â million (inclusive of a $24.0Â million income tax benefit related to executive stock option exercise) in 2020.Net income attributable to Amedisys, Inc. per diluted share of $1.37 compared to $2.16 (inclusive of $0.72 income tax benefit related to executive stock option exercise) in 2020.Adjusted... More
